DTX301

· Ultragenyx Pharmaceutical Inc.

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for DTX301, covering 2022-12-23 to 2026-06-02. Get the full timeline:

Most recent: Clinical Trial Update: Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency [Phase 3]